https://www.mynewsdesk.com/lokon-pharma-ab Mynewsdesk RSS - pressmeddelanden, nyheter och blogginlägg. https://www.mynewsdesk.com/lokon-pharma-ab https://www.mynewsdesk.com/assets/graphics/logos/logo-small-9892f98564f91864075bd14001f8470f2f9bf254729c37044b4b1ac9b0db6b40.png 128 23 sv 15 Tue, 17 Feb 2026 10:44:55 +0000 Final results from the LOKON003 phase 1/2 trial: LOAd703 may re-sensitize therapy resistant melanoma patients to continued checkpoint antibody treatment. https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/results-from-first-melanoma-trial-using-load703-tumor-microenvironment-gene-engineering-in-combination-with-immune-checkpoint-inhibition-is-published-in-nature-communications-3433034?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/results-from-first-melanoma-trial-using-load703-tumor-microenvironment-gene-engineering-in-combination-with-immune-checkpoint-inhibition-is-published-in-nature-communications-3433034?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Lokon Pharma AB Fri, 10 Jan 2025 13:44:36 +0000 Lokon's first clinical product, LOAd703, was granted Fast Track Designation in the U.S. by the FDA for the treatment of pancreatic cancer. LOAd703 is a gene engineering viral vector, a form of immunotherapy, which has shown promising results in early studies. Fast Track will support clinical development as meetings with the FDA can occur more frequently. https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/lokon-pharma-receives-fda-fast-track-designation-for-load703-for-the-treatment-of-pancreatic-cancer-3363162?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/lokon-pharma-receives-fda-fast-track-designation-for-load703-for-the-treatment-of-pancreatic-cancer-3363162?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Lokon Pharma AB Mon, 04 Nov 2024 05:00:00 +0000 Lokon Pharma continues to develop TME gene engineering product for pancreatic cancer in combination with PD-1 antibody therapy. https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/lokon-pharma-announces-collaboration-to-combine-its-tme-gene-engineering-product-with-anti-pd-1-antibody-tislelizumab-in-pancreatic-cancer-3352366?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/lokon-pharma-announces-collaboration-to-combine-its-tme-gene-engineering-product-with-anti-pd-1-antibody-tislelizumab-in-pancreatic-cancer-3352366?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Lokon Pharma AB Tue, 26 Mar 2024 03:58:36 +0000 Lokon Pharma and Baylor College of Medicine have published results from their joint trial testing an immunostimulatory gene therapy for patients with pancreatic cancer in the well renowned journal Lancet Oncology. The clinical data shows a 55% response rate and 91% disease control rate in the highest dose cohort which is higher than one would expect from standard chemotherapy treatment. https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/results-from-first-pancreatic-cancer-trial-using-immunostimulatory-gene-therapy-is-published-in-lancet-oncology-3189395?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/results-from-first-pancreatic-cancer-trial-using-immunostimulatory-gene-therapy-is-published-in-lancet-oncology-3189395?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Lokon Pharma AB Wed, 12 Jan 2022 07:30:03 +0000 https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/lokon-pharma-initiates-a-collaboration-with-affibody-to-develop-novel-cancer-therapeutics-3149941?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/lokon-pharma-initiates-a-collaboration-with-affibody-to-develop-novel-cancer-therapeutics-3149941?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Lokon Pharma AB Fri, 28 Aug 2020 06:00:00 +0000 https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/lokon-pharma-expands-collaboration-with-roche-evaluating-load703-immunostimulatory-gene-cancer-therapy-in-combination-with-tecentriq-r-punkt-punkt-punkt-2891498?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/lokon-pharma-expands-collaboration-with-roche-evaluating-load703-immunostimulatory-gene-cancer-therapy-in-combination-with-tecentriq-r-punkt-punkt-punkt-2891498?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Lokon Pharma AB Wed, 03 Jul 2019 06:31:44 +0000 An agreement between Lokon Pharma and Roche..... https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/lokon-pharma-announces-collaboration-to-combine-load703-oncolytic-virotherapy-with-checkpoint-blockade-in-pancreatic-cancer-and-melanoma-2891472?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/lokon-pharma-announces-collaboration-to-combine-load703-oncolytic-virotherapy-with-checkpoint-blockade-in-pancreatic-cancer-and-melanoma-2891472?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Lokon Pharma AB Thu, 19 Jan 2017 12:14:07 +0000 https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/first-patient-treated-by-a-novel-oncolytic-virus-armed-with-immune-stimulators-1752128?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/lokon-pharma-ab/pressreleases/first-patient-treated-by-a-novel-oncolytic-virus-armed-with-immune-stimulators-1752128?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Lokon Pharma AB